Fig. 1

Elevated expression of E2F7 correlates with TMZ resistance and predicts an adverse prognosis. (A) Volcano plot analysis illustrating the differentially expressed genes in TMZ-sensitive (TMZ-S) and TMZ-resistance (TMZ-R). (B) The top enriched gene categories were identified by GenePattern based on genes positively correlated with TMZ-R. A NES value of 1.0 and p < 0.05 were used as visual thresholds. (C) Rank diagram displaying the top 50 differentially expressed genes in TMZ-R and TMZ-S tumors at the mRNA level. (D, E) The expression of E2F7 in TMZ-S and TMZ-R tissue measured by RT-qPCR (C) and Western blot (D) (n = 3, **p < 0.01). β-Tubulin served as a loading control. (F) Representative IF images of the E2F7 expression in the same glioma tissue sections (scale bars, 50 μm). The immunoreactivity score (IRS) of E2F7 is displayed on the right side. NB, Normal Brain; LGG, Lower Grade Glioma; GBM, Glioblastoma multiforme. (G) The expression of E2F7 in different grades of gliomas in the Gliovis-Rembrandt and Gliovis-Gravendeel databases. NT, non-tumor brain tissues; Ast, astrocyte; Olig, oligodendrocyte; GBM, glioblastoma multiforme. (H) Overall survival analysis based on E2F7 expression in the indicated GBM datasets. (I) GSEA analysis according to TCGA_GBM data derived from Linked-Omic. (J) Top 10 gene sets analyzed by GO and KEGG.